EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Serum glial fibrillary acidic protein predicts disease progression in multiple sclerosis

Evan Madill, Brian C Healy, Negar Molazadeh, Mariann Polgar-Turcsanyi, Bonnie I Glanz, Howard L Weiner, Tanuja Chitnis iD

Annals of Clinical and Translational Neurology · 2024

DOI: 10.1002/acn3.52187 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2024. Verfasst von Evan Madill und 6 weiteren Autor:innen. Beteiligte Einrichtung: Brigham Multiple Sclerosis Center, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Glial Fibrillary Acidic Protein, Multiple Sclerosis. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: American Academy of Neurology, Defense Human Resources Activity.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Glial fibrillary acidic protein (GFAP) is expressed in astrocytes and may be a useful marker of non‐active progressive multiple sclerosis (MS). We evaluate serum GFAP (sGFAP) in a large cohort of MS patients to determine if it predicts progression independent of relapse activity (PIRA), future gait aid, and conversion to secondary progressive disease (SPMS).

Methods

Adults with clinically isolated syndrome or any subtype of MS who were listed in the Brigham MS Center Research Database and had at least one sGFAP result were included. All clinic visits following first sample were analyzed for PIRA, future gait aid, and conversion to SPMS. Future cognitive dysfunction and fatigue were evaluated as secondary outcomes.

Results

In total, 741 patients were included (average age: 42.3, average disease duration: 3.7 years, median EDSS: 2, and median follow‐up duration: 10.0 years). Of 643 patients (86.8%) without progressive disease at baseline, 15.9% developed SPMS. Among all 741, 50.5% had PIRA and 18.6% developed a gait aid requirement. sGFAP level predicted PIRA, future gait aid, and conversion to SPMS in univariable models ( p < 0.001,

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glial Fibrillary Acidic ProteinMultiple SclerosisAdultFemaleHumansMaleMiddle AgedBiomarkersCognitive DysfunctionDisease ProgressionMultiple Sclerosis, Chronic Progressive

Substanzen

BiomarkersGFAP protein, humanGlial Fibrillary Acidic Protein

Autor:innen und Institutionen

  • Brigham Multiple Sclerosis Center, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Tanuja Chitnis

Förderung

  • American Academy of Neurology
  • Defense Human Resources Activity

Zitieren

APA

Madill, E., Healy, B. C., Molazadeh, N., Polgar-Turcsanyi, M., Glanz, B. I., Weiner, H. L., & Chitnis, T. (2024). Serum glial fibrillary acidic protein predicts disease progression in multiple sclerosis. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.52187

Vancouver

Madill E, Healy BC, Molazadeh N, Polgar-Turcsanyi M, Glanz BI, Weiner HL, et al. Serum glial fibrillary acidic protein predicts disease progression in multiple sclerosis. Annals of Clinical and Translational Neurology. 2024. doi:10.1002/acn3.52187

BibTeX
@article{Madill2024,
  author = {Madill, Evan and Healy, Brian C and Molazadeh, Negar and Polgar-Turcsanyi, Mariann and Glanz, Bonnie I and Weiner, Howard L and Chitnis, Tanuja},
  title = {Serum glial fibrillary acidic protein predicts disease progression in multiple sclerosis},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2024},
  doi = {10.1002/acn3.52187}
}
Kostenlos starten →